Examine Future Forecasts for the Neuroprotection - Drugs Markets to 2015.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c1364) has announced the addition of the Jain PharmaBiotech report: Neuroprotection - Drugs, Markets and Companies to their offering. This report describes the role of neuroprotection in acute disorders such as stroke and injuries of the nervous system as well as in chronic diseases such as neurodegenerative disorders because many of the underlying mechanisms of damage to neural tissues are similar in all these conditions and several products are used in more than one disorder. Over 500 products have been investigated for neuroprotective effects including those from the categories of free radical scavengers, anti-excitotoxic agents, apoptosis (programmed cell death pro·grammed cell death n. See apoptosis. programmed cell death proposed system of cell death, often including poly(ADP)-ribosylation, ensures that a cell will not survive if it is so badly damaged that its recovery would harm the ) inhibitors, anti-inflammatory agents, neurotrophic factors, metal ion chelators, ion channel ion channel n. See channel. modulators and gene therapy. Some of the agents are old established pharmaceuticals whereas others are new biotechnology products. Pathomechanisms of diseases are described with steps at which neuroprotective therapies are directed. Diseases covered include cerebrovascular cer·e·bro·vas·cu·lar adj. Relating to the blood supply to the brain, particularly with reference to pathological changes. cerebrovascular pertaining to the blood vessels of the cerebrum or brain. disorders, traumatic brain injury Traumatic brain injury (TBI), traumatic injuries to the brain, also called intracranial injury, or simply head injury, occurs when a sudden trauma causes brain damage. TBI can result from a closed head injury or a penetrating head injury and is one of two subsets of acquired brain , spinal cord injury Spinal Cord Injury Definition Spinal cord injury is damage to the spinal cord that causes loss of sensation and motor control. Description Approximately 10,000 new spinal cord injuries (SCIs) occur each year in the United States. , Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis amyotrophic lateral sclerosis (ALS) (ā'mīətrōf`ik, sklĭrō`sĭs) or motor neuron disease, , multiple sclerosis, epilepsy and ischemic optic neuropathy Ischemic optic neuropathy (ION) is the loss of structure and function of a portion of the optic nerve due to obstruction of blood flow to the nerve (i.e. ischemia). ION is typically classified as either anterior ischemic optic neuropathy or posterior ischemic optic neuropathy as well as retinal degeneration. Although anesthetics Anesthetics Drugs or methodologies used to make a body area free of sensation or pain. Mentioned in: Appendectomy such as propofol are neuroprotective as well, neuroprotection during surgery and anesthesia is discussed with the aim of preventing and treating complications that result in CNS See Continuous net settlement. CNS See continuous net settlement (CNS). damage. The report contains a profile of 121 companies that have a neuroprotective product or products along with 81 collaborations. Some of the products in development at academic institutions that do not have a commercial sponsor are also included. Although an up-to-date search of the literature was performed and selected 650 references are included, a considerable amount of information has not been published anywhere else. Clinical trials of various neuroprotective agents are described and failures of trials in stroke and head injury are analyzed with suggestions for improving the selection of drugs and design of trials. The report is supplemented with 59 tables and 9 figures. Market analysis of currently used products that have a neuroprotective effect are analyzed for the year 2006. Some of these products are approved for other indications but are known to have a neuroprotective effect. With the approval of new products and takeover of markets for obsolete symptomatic therapies, the neuroprotection market value will rise by the year 2010 when it will constitute a major and important component of the CNS market. Forecasts are made until 2015. By that time neuroprotection will be an established part of the neurological practice and measures will be available to achieve this effectively. Topics Covered 0. Executive Summary 1. Introduction 2. Neuroprotective Agents 3. Neuroprotection in Cerebrovascular Disease 4. Neuroprotection in CNS Trauma 5. Neuroprotection in Neurodegenerative Disorders 6. Neuroprotection in Miscellaneous Neurological Disorders 7. Neuroprotection during Anesthesia and Surgery 8. Commercial aspects of Neuroprotective Therapy TABLES FIGURES For more information visit http://www.researchandmarkets.com/reports/c1364 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion